Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Date publication

juin 2019

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno , Pr PIVOT Xavier

Tous les auteurs :
Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31172407

Résumé

Metastatic triple-negative breast cancer (TNBC) is a phenotypic breast cancer subgroup with a very poor prognosis, despite standard treatments. Combined twice-weekly iniparib and gemcitabine/carboplatin (GC+tw-iniparib) showed benefit over gemcitabine/carboplatin in a randomized phase II trial, and a phase III was initiated comparing these regimens. The present phase II study was initiated to compare GC+tw-iniparib with a more practical once-weekly schedule (GC+w-iniparib) in TNBC.

Mots clés

Administration schedule, Iniparib, Metastatic triple-negative breast cancer, Pharmacokinetics

Référence

Breast Cancer Res. Treat.. 2019 Jun 6;: